“`html
hormone Therapy Does Not Increase Dementia Risk, Major New Study Finds
Table of Contents
A comprehensive analysis of over a million women’s data offers reassurance regarding the safety of hormone therapy, debunking previous concerns about a potential link to increased dementia risk.
The anxiety surrounding this issue is understandable. Women are significantly more likely to develop dementia than men, both globally and within Germany. The ratio stands at approximately 3:2. According to an analysis of global data, around 80 out of every 1,000 women over the age of 65 are expected to experience dementia, compared to “only” 55 out of 1,000 men. While age – the fact that women, on average, live longer than men – is a contributing factor, it doesn’t fully explain the disparity.
Initial Concerns Sparked by Past Research
A legitimate suspicion arose regarding hormone therapies, notably after a large Danish study revealed an approximately 24% increased relative risk of dementia with the use of so-called estrogen-gestagen therapy, a risk that increased with longer duration of use. This finding prompted further examination into the potential impact of hormonal interventions on cognitive health.
Hormone Therapy Guidelines in Germany
Current German guidelines, outlined in the “peri- and Postmenopause – Diagnosis and Interventions” document, recommend hormone therapy for women experiencing significant discomfort that substantially impacts their quality of life. Thes recommendations include estrogen-gestagen combinations for women with a uterus and estrogen-only therapy for those who have undergone a hysterectomy, ideally administered transdermally – through the skin.
Hormone therapies are designed to alleviate symptoms associated with menopause, frequently enough triggered by a sudden decline in estrogen levels. However, if hormone management were to actually cause dementia, any short-term improvements in well-being during menopause woudl come at a significant long-term cost.
New Study Offers Reassurance
Fortunately, new research led by British researcher Melissa Melville, published on December 22nd in the journal Lancet Health Longevity, provides a welcome clarification: hormone therapies do not increase the risk of dementia, nor do they prevent it. To ensure robust findings, the researchers evaluated and compared data from ten studies encompassing more than one million women. They found “no evidence that the use of menopausal hormone therapy (MHT) either increases or decreases the risk of dementia in postmenopausal women,” they stated.
Minimal Difference in dementia Rates
Previous studies had created uncertainty among women. The Danish study and the WHIMS study from the United States (2003) were particularly prominent in generating headlines. The WHIMS study indicated that women who began combined hormone therapy at age 65 or older had roughly double the relative risk of dementia.
The new analysis by Melville and her colleagues reframes these earlier findings. The absolute increase in risk was, in fact, relatively small. Ultimately, the authors conclude that MHT, even at older ages, “likely makes little or no difference” to dementia risk.
Understanding the Research Methodology
The comprehensive meta-analysis involved a rigorous review of existing literature, combining data from multiple sources to achieve a statistically significant sample size. This approach strengthens the reliability and generalizability of the findings.
Related reading
